Article Text

other Versions

Download PDFPDF
A longitudinal study of sexual health and quality of life in endometrial carcinoma survivors
  1. Amrita Datta1,
  2. Thomas S Ram2,
  3. Reka Karuppusami3,
  4. Anitha Thomas1,
  5. Ajit Sebastian1,
  6. Vinotha Thomas1,
  7. Rachel George Chandy1 and
  8. Abraham Peedicayil1,4
  1. 1Gynaecologic Oncology, Christian Medical College and Hospital Vellore, Vellore, Tamil Nadu, India
  2. 2Radiation Oncology, Christian Medical College and Hospital Vellore, Vellore, Tamil Nadu, India
  3. 3Biostatistics, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  4. 4Gynecologic Oncology, Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, Oman
  1. Correspondence to Dr Abraham Peedicayil, Gynecologic Oncology, Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, 135, Oman; apeedicayil{at}yahoo.com

Abstract

Objectives This study aimed to assess sexual health and quality of life (QoL) in endometrial cancer survivors and the factors influencing these variables.

Methods A mixed method design comprising quantitative (cohort design) and qualitative (face-to-face interviews) aspects was chosen. A total of 132 patients who underwent surgery alone, surgery followed by adjuvant vaginal brachytherapy, or surgery followed by chemotherapy and radiation were included. Female Sexual Function Index (FSFI) and Functional Assessment of Cancer Therapy General (FACT-G) questionnaires were used to assess the participants’ sexual health and QoL at 6 months and 1 year post-treatment. Multivariate logistic regression models were used to analyze the factors associated with general and sexual well-being.

Results At 1 year, 89% of the participants still had low sexual function scores. Survivors over 50 years (OR 284.7, 95% CI 13 to 364, p<0.001) and educated below graduate level (OR 26.8, 95% CI 2 to 370, p=0.014) had low sexual function scores. Patients who had surgery alone had better QoL than those who received adjuvant radiation. Women who had surgery, chemotherapy, and radiation had the lowest QoL scores (OR 6.4, 95% CI 2.1 to 19.5, p=0.001). All scores improved with time.

Conclusions This study demonstrated the high prevalence of low sexual function and poor QoL in endometrial cancer survivors. There was a communication gap between the women and their partners as well as their healthcare providers. This study highlights the need for discussion about the survivors’ sexual well-being and QoL.

  • Surgery
  • Radiotherapy
  • Uterine Cancer
  • Quality of Life (PRO)/Palliative Care

Data availability statement

Data are available upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text

Footnotes

  • Contributors AP and TSR conceptualized and designed the study. AD collected the data and drafted the initial manuscript. RK performed the statistical analyses. All authors critically reviewed the earlier versions of the manuscript and approved the final submitted version. AP is responsible for the overall content as guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.